CLSN Celsion Corp.

Celsion Corporation to Participate in Two Investor Conferences in May 2019

Celsion Corporation to Participate in Two Investor Conferences in May 2019

  Company to Discuss its Ongoing Pivotal Phase III Study in Primary Liver Cancer and its Phase I/II Clinical Study in Ovarian Cancer

LAWRENCEVILLE, N.J., April 12, 2019 (GLOBE NEWSWIRE) --   (NASDAQ: CLSN), an oncology drug development company, today announced that Michael Tardugno, Chairman, President and Chief Executive Officer and Jeffrey Church, Executive Vice President and Chief Financial Officer, will attend the following upcoming investor conferences:

  • The ThinkEquity Conference on Thursday, May 2, 2019 at The Mandarin Oriental Hotel in New York City.

     
  • The Deutsche Bank 44th Annual Health Care Conference on Tuesday, May 7, 2019 and Wednesday, May 8, 2019 at The InterContinental Hotel in Boston.

A webcast of Celsion’s presentation at the ThinkEquity Conference may be accessed by visiting the “News & Investors” section of Celsion’s corporate website at .com. The format of the Deutsche Bank Health Care Conference will only be comprised of one-on-one and small group meetings with leading institutional investors.

About Celsion Corporation

Celsion is a fully-integrated oncology company focused on developing a portfolio of innovative cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies. The Company's lead program is ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, currently in Phase III development for the treatment of primary liver cancer and in development for other cancer indications. The Company’s product pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies. For more information on Celsion, visit our website: . (CLSN-FIN).

ThermoDox® is a registered trademark of Celsion Corporation.

Celsion Investor Contact

Jeffrey W. Church

Executive Vice President & CFO

609-482-2455

EN
12/04/2019

Underlying

CLSNCelsion Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsion Corp.

 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON Reports Interim Progression-Free Survival and Overall Survival ...

IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow-up is indicated to confirm initial observations LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and next-generation vaccines, announces int...

September 28, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, V...

IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced the release of an enterprise video that highlights the company’s mission, vision, values, breakthroughs and technolog...

September 26, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ...

IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, reminds investors of its virtual R&D Day event tomorrow, September 14th beginning at 4:00 p.m. Eastern time. There is no need to pre-register for the event. A live and archived webcast will be available in th...

September 13, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m...

IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that it will hold a virtual R&D Day event on September 14th beginning at 4:00 p.m. Eastern time. Details about speakers and instructions on how to participate are below. ...

September 7, 2023 1 EN
 PRESS RELEASE
Free
CLSN CELSION CORP.

IMUNON to Participate in the H.C. Wainwright Global Investment Confere...

IMUNON to Participate in the H.C. Wainwright Global Investment Conference LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023. A webcast of the IMUNON presentation will be available on the section of the Company’s website beginning Monday, September 11 at 7:00 a.m. Eastern time. Management is available throughout the conference for virtual one-on-one meetings. Institutional inv...

September 5, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch